Market Interview
Our Focus is to Address The Requirements of Our Customers First Innovations in the Image-Guided Therapy segment is one of its key focus areas in India. Nitin Stephen Abel, Business Leader, Image-Guided Therapy, Philips Indian Subcontinent, talks about the company's innovations in this space, and how it has aligned with the Indian government's 'Make in India' drive
Can you tell us what the Philips Image Guided Therapy business is all about? Philips develops solutions to help its customers decide, guide, treat and then confirm the right care, for every patient, in real-time.
Nitin Stephen Abel, Business Leader, Image-Guided Therapy, Philips Indian Subcontinent
Our focus is to address the requirements of our customers first, keeping the patients at the centre of everything we do, in line with our objective to achieve, what we call the ‘Quadruple-Aim’ i.e. to have better clinical outcomes, improved patient experience, improved staff experience and lowering the cost of care. We combine meaningful innovation with evidence-based technologies to simplify workflows while enhancing patient care and reducing the overall cost. Patients with coronary artery disease, peripheral artery disease or lead extraction indications benefit from our integrated solutions that enhance the art of minimally invasive procedures. Our product portfolio consists of interventional imaging systems (cathlabs and mobile c-arms), smart devices, software and services. We have a full range of products that the customers can opt for depending on their clinical needs.
32
January 2022
We constantly innovate and strive to expand therapeutic indications in cardio, neuro, spine, ortho, onco etc. with the focus to drive care with better clinical outcomes and high productivity. Can you outline Philips’ innovations in the Image-Guided Therapy space? In the Image-Guided Therapy arena, we constantly push ourselves to innovate minimally invasive procedures in a growing number of therapeutic segments, with significantly better clinical outcomes and high productivity. We further plan to expand our portfolio through the acquisition of many more similar companies that suit our strategic fit, like the recent one being Vesper Medical for the treatment of deep venous disease. With such synergies, we provide clinicians with a complete procedural solution for the treatment of myriad complex diseases. Furthermore, we are expanding in newer therapy areas such as neuro, spine, ortho and oncology and continuously innovating to bring in solutions such as the first spectral detector angio-CT solution that combines breakthrough spectral detector CT-imaging and real-time fluoroscopy in a flexible environment where all modalities are
